Commenting on the quarter, David B. McWilliams, chief executive officer of Opexa, stated, "This has been a very dynamic and rewarding time for Opexa. We implemented an important capital restructuring and name change during the quarter, and completed a $23 million financing that provides the financial underpinnings for our Phase IIb trial with Tovaxin and funds our other business activities. We also strengthened our corporate governance with the addition of four new directors, each of whom brings a valuable skill set and perspective to Opexa."
http://www.genengnews.com/news/bnitem.aspx?name=4681986